Pharmacokinetics of FDL169 in Healthy Female Subjects

Cystic Fibrosis Clinical Trial

Official title:

A Phase I Dose Escalation Study to Assess the Pharmacokinetics (PK) of FDL169 in Healthy Female Volunteers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02680418
• Other study ID #: FDL169-2015-02
• Status: Recruiting
• Phase: Phase 1
• First received: February 2, 2016
• Last updated: February 8, 2016
• Start date: December 2015
• Est. completion date: February 2016

Study information

• Verified date: February 2016
• Source: Flatley Discovery Lab LLC
• Contact: Timothy Hardman, BSc, PhD
• Phone: +44 20 8332 2588
• Email: tim.hardman[@]niche.org.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

To determine the pharmacokinetics of single and multiple doses of FDL169 in healthy female subjects.

Description:

This is a two-part study.

Part 1:

Part 1 of the study is a single-dose, dose-escalation, study to assess the safety, tolerability and PK profiles following oral administrations of FDL169 to healthy female volunteers in the fed state. Up to five doses will be assessed.

Part 2:

Part 2 of the study is a multiple-dose study to assess the safety, tolerability and PK profiles following oral administrations of FDL169 to healthy female volunteers in the fed state.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy female subjects aged 18 to 55 years inclusive and of any ethnic origin with a body mass index (BMI) of > 19 and < 30 kg/m2. Body Mass Index = Body weight (kg) / [Height (m)]

2. Subjects must be willing to use an effective method of contraception from first dose of investigational medicinal product (IMP) and for 3 months after the last dose of IMP (unless they are of non-child bearing potential).

Exclusion Criteria:

1. Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months.

2. Subjects who have any renal or clinically significant cardiac, renal or hepatic disease at Screening.

3. Subjects who have history or presence of clinically significant cardiovascular, pulmonary, renal, hepatic, haematologic, gastrointestinal (with the exception of Gilbert's syndrome or asymptomatic gallstones), endocrine or immunologic disease at Screening.

4. Have an abnormal twelve-lead ECG or an ECG with abnormality considered to be clinically significant in the opinion of the Investigator or an ECG with a single QTcB > 450 mSec.

5. Subjects with a positive urinary drugs of abuse screen or positive alcohol screen at Screening or Day -1.

6. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of > 21 units.

7. Subject with history of HIV or positive human immunodeficiency virus, hepatitis B or hepatitis C results.

8. Donation of 500 mL or more of blood within the previous 3 months.

9. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and FDL Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

10. Smoking or use of tobacco products or substitutes equivalent to > 15 cigarettes/day.

11. Any subject who is pregnant or nursing.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Cystic Fibrosis

Intervention

Drug:
• FDL169

Locations

Country	Name	City	State
United Kingdom	Simbec Research Ltd	Merthyr Tydfil	Wales

Sponsors (1)

Lead Sponsor	Collaborator
Flatley Discovery Lab LLC

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Maximum plasma concentration of FDL169 (and metabolites) over 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dose	No
Primary	Part 1: Time to maximum plasma concentration of FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: Individual estimate of the terminal elimination rate constant of FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: Terminal half-life of FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: AUC from the time of dosing to the time of the last observed concentration for FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: AUC extrapolated to infinity from dosing time, based on the last observed concentration for FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: Clearance of FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 1: AUC% extrapolated for FDL169 (and metabolites) during 48 h following single oral doses of FDL169		Multiple points from pre-dose to 48 h post-dosing on Day 7	No
Primary	Part 2: Maximum plasma concentration of FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: Time to maximum plasma concentration of FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: Individual estimate of the terminal elimination rate constant of FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: Terminal half-life of FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: AUC from the time of dosing to the time of the last observed concentration for FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: AUC extrapolated to infinity from dosing time, based on the last observed concentration for FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: AUC from the time of dosing to time t at steady state for FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: Clearance of FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Primary	Part 2: AUC% extrapolated for FDL169 (and metabolites) following multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post-final dose)		Multiple points from pre-dose to 48 h post-final dose	No
Secondary	Number of patients with clinically significant changes in systolic blood pressure following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with clinically significant changes in diastolic blood pressure following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with clinically significant changes in pulse rate following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with clinically significant changes in oxygen saturation following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with clinically significant changes in oral temperature following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with clinically significant 12-lead ECG abnormalities following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients with abnormal laboratory values following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No
Secondary	Number of patients experiencing treatment-related adverse events following single and multiple oral doses of FDL169 (assessed throughout dosing and for 48 h post (final) dose)		Multiple points from pre-dose to 48 h post (last) dose	No